Please assess the completion status of the following clinical trial:

Trial Title: Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven prostate cancer~* Know metastatic disease on previous imaging, or PSA value ⩾ 1 ng/ml;~* Castration resistant disease with confirmed testosterone level =\< 50 ng/ml under prior first-line androgen deprivation therapy (ADT)~* New planned treatment with enzalutamide or abiraterone, darolutamide or apalutamide~* Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist~* Stated willingness to comply with continuation of ARSI treatment for the duration of the study~* Provision of signed and dated informed consent form~Exclusion Criteria:~* Inability to provide written informed consent~* Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)~* Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy~* A baseline superscan pattern on bone scan~* Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (68GA-PSMA-11 PET/CT) (Type: EXPERIMENTAL): Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).